Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> BACKGROUND</h3><p>Although both PSA nadir (PSAn) and testosterone levels at PSA failure are known prognostic factors in men undergoing radiation therapy (RT) and androgen deprivation therapy (ADT) for unfavorable‐risk prostate cancer (PC), it is unclear whether their prognostic significance is independent or overlapping.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> METHODS</h3><p>Seventy‐five men treated with RT with or without 6 months of ADT for unfavorable‐risk nonmetastatic PC enrolled in 2 prospective clinical trials between 1986 and 2001 formed the study cohort. Competing risks and Cox multivariable regression were used to assess whether low versus normal serum testosterone at the time of PSA failure and higher PSAn after initial therapy were independently associated with the risk of PC‐specific (PCSM) and all‐cause mortality (ACM) adjusting for PC prognostic factors.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> RESULTS</h3><p>After a median follow‐up of 15.34 years (interquartile range, 6.66‐16.88 years), there were 53 deaths (73.3%): 30 (56.6%) were from PC. Low testosterone at PSA failure was significantly associated with an increased risk of PCSM (adjusted HR [AHR], 7.77; 95% CI, 1.14‐52.99; <i>P</i> = .04) and ACM (AHR, 3.01; 95% CI, 1.01‐8.96; <i>P</i> = .05), as was higher PSAn (PCSM AHR, 1.03; 95% CI, 1.01‐1.05; <i>P</i> < .01; ACM AHR, 1.04; 95% CI, 1.02‐1.07; <i>P</i> < .01), although the prognostic significance of PSAn was only noted in men with a normal testosterone at PSA failure. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> CONCLUSIONS</h3><p>Low testosterone level at PSA failure in high‐risk patients with PC treated with RT is associated with increased PCSM and ACM risk. In men with normal testosterone levels at the time of PSA failure, an elevated PSAn was associated with worse PCSM and ACM risk.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> LAY SUMMARY</h3><p>This study investigates whether the prostate‐specific antigen (PSA) nadir and normal versus low testosterone at the time of PSA failure provide mutually exclusive or overlapping prognostic information following treatment with radiation and androgen deprivation therapy for unfavorable‐risk patients with prostate cancer using data from 2 prospective clinical trials. It was found that both provided prognostic information; however, higher PSA nadir was only found to be of prognostic significance in men with normal testosterone levels at PSA failure.</p></section>

What problem does this paper attempt to address?

### What problem does this paper attempt to solve? This paper aims to explore whether the prostate-specific antigen nadir (PSAn) and testosterone levels at the time of prostate-specific antigen failure provide independent or overlapping prognostic information in patients with unfavorable-risk prostate cancer (PC) undergoing radiotherapy (RT) and androgen deprivation therapy (ADT). Specifically, the study evaluates the risk differences in prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) between low testosterone levels and normal testosterone levels at the time of PSA failure by analyzing data from 2 prospective clinical trials. It also examines the prognostic significance of PSAn in these patients. The study finds that a higher PSAn has significant prognostic value only in patients with normal testosterone levels, whereas in patients with low testosterone levels, PSAn does not differentiate between different risk groups.

Prostate‐specific antigen nadir and testosterone level at prostate‐specific antigen failure following radiation and androgen suppression therapy for unfavorable‐risk prostate cancer and the risk of all‐cause and prostate cancer–specific mortality